# A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

> **NCT01294709** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 64 (actual)

## Conditions studied

- Angina Pectoris
- Coronary Heart Disease
- Calcitonin Gene-related Peptide Receptor

## Interventions

- **DRUG:** telcagepant
- **DRUG:** Placebo to telcagepant

## Key facts

- **NCT ID:** NCT01294709
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-12
- **Primary completion:** 2009-02-28
- **Final completion:** 2009-03-13
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294709, "A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01294709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*